HomeAI · summaries
Storia in 2 fonti
Compass Pathways touts durability data for psilocybin drug in depression ahead of year-end filing
Compass Pathways is on track to complete its NDA filing for treatment-resistant depression by the end of the year despite a stock drop.
Confronto fonti
2 prospettive sulla stessa storiaTimeline cronologica
- ·
endpoints.news
Compass Pathways touts durability data for psilocybin drug in depression ahead of year-end filing
Compass Pathways is on track to complete its NDA filing for treatment-resistant depression by the end of the year despite a stock drop.
- ·
benzinga.com
Compass Pathways Highlights Data, Backs 2027 Launch Timeline - Compass Pathways (NASDAQ:CMPS)
Compass Pathways reported positive 26-week Phase 3 COMP360 data for treatment-resistant depression as its FDA filing remains on track.